News & Updates

Show Multimedia Only

Conversion to resectability uncommon in trials of unresectable mCRC patients

04 Aug 2022

In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.

Conversion to resectability uncommon in trials of unresectable mCRC patients

04 Aug 2022

Abiraterone-olaparib confers clinical benefit for mCRPC patients

04 Aug 2022 by

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.

Abiraterone-olaparib confers clinical benefit for mCRPC patients

04 Aug 2022

70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients

04 Aug 2022

MammaPrint, a signature test that includes 70 genes, appears to accurately identify hormone receptor-positive breast cancer (HR+BC) patients who are at ultra-low risk of distant recurrence, reports a recent study.

70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients

04 Aug 2022

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

03 Aug 2022 by

Photodynamic therapy using topically applied hypericin 0.25% is effective against early-stage patch and plaque lesions in patients with mycosis fungoides−cutaneous T-cell lymphoma, while having a favourable safety profile, as shown in the phase III FLASH trial.

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

03 Aug 2022

Bone surgery at lower-volume hospitals does not compromise survival, readmission

03 Aug 2022

Surgical treatment for metastatic disease of bone (MDB) at lower-volume hospitals is not associated with poorer survival or more readmissions, according to a study.

Bone surgery at lower-volume hospitals does not compromise survival, readmission

03 Aug 2022

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

03 Aug 2022 by

The addition of erlotinib to best supportive care (BSC) provided better survival benefit than BSC only in individuals with unresectable/metastatic gall bladder cancer (GBC) with poor performance status (PS), according to a phase II/III open-label study.

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

03 Aug 2022

Healthy living key to reducing lethal prostate cancer risk

02 Aug 2022 by

Adhering to a healthy lifestyle may be a means to counteract the genetic risk of lethal prostate cancer, a study finds.

Healthy living key to reducing lethal prostate cancer risk

02 Aug 2022

Online intervention shows promise in psych support for partners of cancer patients

31 Jul 2022

PartnerCARE, an online intervention designed to address mental health needs of caregiving partners of cancer patients, appears to be feasible and acceptable, a recent study has found. PartnerCARE also appears to be effective, inducing substantial improvements in psychological distress and anxiety.

Online intervention shows promise in psych support for partners of cancer patients

31 Jul 2022

Many cancer patients cannot cope with depressive symptoms

31 Jul 2022

A large proportion of cancer patients suffering from depressive symptoms cannot seem to effectively manage this burden on their own, particularly those who tend to avoid dealing with their own problems, reports a recent analysis.

Many cancer patients cannot cope with depressive symptoms

31 Jul 2022

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

31 Jul 2022

New drug applications approved by US FDA as of 16 - 31 July 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

31 Jul 2022

News & Updates

Filter by Specialty:

Specialty:

Conversion to resectability uncommon in trials of unresectable mCRC patients

Conversion to resectability uncommon in trials of unresectable mCRC patients

Abiraterone-olaparib confers clinical benefit for mCRPC patients

Abiraterone-olaparib confers clinical benefit for mCRPC patients

70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients

70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

Bone surgery at lower-volume hospitals does not compromise survival, readmission

Bone surgery at lower-volume hospitals does not compromise survival, readmission

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

Healthy living key to reducing lethal prostate cancer risk

Healthy living key to reducing lethal prostate cancer risk

Online intervention shows promise in psych support for partners of cancer patients

Online intervention shows promise in psych support for partners of cancer patients

Many cancer patients cannot cope with depressive symptoms

Many cancer patients cannot cope with depressive symptoms

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)